Marker Therapeutics Competitors and Similar CompaniesClear all

Marker Therapeutics's competitors and similar companies include Celldex Therapeutics and Advaxis.
Marker Therapeutics
Marker Therapeutics
Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection.
Celldex Therapeutics
Celldex Therapeutics
Celldex Therapeutics (formerly Avant Immunotherapeutics) is a biopharmaceutical company that specializes in monoclonal and bispecific antibodies development.
Advaxis
Advaxis
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Founding Date
Founding Date
2018
Founding Date
1983
Founding Date
2002
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Houston, US HQ
Locations
Hampton, US HQ
Fall River, US
Needham, US
New Haven, US
Locations
Princeton, US HQ
Employees
Employees
888% decrease
Employees
1608% increase
Employees
3540% decrease
Valuation ($)
Valuation ($)
36.5 m
Valuation ($)
1.9 b
Valuation ($)
2.4 m

Financial

Revenue (est.)
Revenue (est.)
$3.5m (FY, 2025)
Revenue (est.)
$1.5m (FY, 2025)
Revenue (est.)
$13k (FY, 2023)
Cost of goods
Cost of goods
N/A
Cost of goods
$200k (FY, 2025)
Cost of goods
$13k (FY, 2023)
Net income
Net income
($12.2m) (FY, 2025)
Net income
($258.8m) (FY, 2025)
Net income
($48.1m) (FY, 2023)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 2m
Total funding raised
$ 50.5m
For sources of this data, please see the company profile

View Company Profiles

Celldex Therapeutics
HQ
Hampton, US
Employees
160↑ 8% increase

Celldex Therapeutics (formerly Avant Immunotherapeutics) is a biopharmaceutical company that specializes in monoclonal and bispecific antibodies development.

View company
Advaxis
HQ
Princeton, US
Employees
35↓ 40% decrease

Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.

View company